RT Conference Proceedings
T1 Safety and efficacy of ponatinib in real world clinical practice. Results from the Spanish Compassionate Use Program. A GELMC study
A1 Valentin, GG
A1 Hernandez-Boluda, JC
A1 Osorio, S
A1 Correa, JG
A1 Sanchez-Guijo, F
A1 Gómez-Casares, MT
A1 Durán, S
A1 Portero, MA
A1 Boqué, C
A1 Pérez-Encinas, M
A1 Mata, MI
A1 Romo, MA
A1 Vallansot, R
A1 Payer, A
A1 Noya, MS
A1 Caballero, G
A1 Ramirez Sánchez, MJ
A1 Jimenez-Velasco, A
A1 Steegmann, JL
K1 Humanos
K1 Imidazoles
K1 Leucemia mielogenosa crónica BCR-ABL positiva
K1 Piridacinas
K1 Riesgo
AB Aims: The purpose of this study is to provide safety and efficacy informationfrom patients treated with ponatinib in real world clinical practice.
PB Ferrata Storti Foundation
SN 0390-6078
YR 2016
FD 2016-06
LK http://hdl.handle.net/10668/2441
UL http://hdl.handle.net/10668/2441
LA en
NO Valentin GG, Hernandez-Boluda JC, Osorio S, Correa JG, Sanchez-Guijo F, Gómez-Casares MT, et al.Safety and efficacy of ponatinib in real world clinical practice. Results from the Spanish Compassionate Use Program. A GELMC study. Haematologica. 2016; 101 (s1) PB1832
DS RISalud
RD Apr 7, 2025